 |
|
            |
| Access educational resources for your patients to help them better understand and manage their CML. Learn more > |
| Since its development, Glivec® has been a cornerstone of therapy for CML patients. Learn more > |
Reviewing the Latest Recommendations in CML Management
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 leading cancer centers in the US, publishes evidence-based clinical practice guidelines for CML. The guidelines detail specific recommendations based on patients’ cytogenetic responses to treatment, including targeted therapy. To download the NCCN’s clinical practice guidelines for CML, click here. The European LeukemiaNet (ELN), a not-for-profit association of scientists from 22 countries, has published recommendations proposing a schedule of response expectations at various time points of targeted therapy for Ph+ CML, including continued molecular monitoring during targeted therapy. To download the ELN panel’s recommendations for CML, click here. (Subscription to Blood required for free access to full text.) If you experience difficulties when attempting to view the above-listed documents simply right-click on the link for the document you wish to view and choose the "Save Target As" or "Save As" option. You'll be prompted for a location to save the report. Save it to a location on your computer and open the document from there. Get the Adobe® PDF Viewer |
|
See European Summary of Product Characteristics Glivec® 100 mg film coated tablets (PDF) Glivec® 400 mg film coated tablets (PDF) Glivec® 50 mg capsules, hard (PDF) Glivec® 100 mg capsules, hard (PDF)
About CML Alliance | Treating CML | Targeted Therapies and CML Contact | Site Map | Privacy |
© Novartis AG |